{"entity":{"id":"nct06378593","kind":"trial","name":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","aka":[],"tldr":"A phase 1/2 trial of 3HP-2827 in advanced solid tumours, run by 3H (Suzhou) Pharmaceuticals Co., Ltd., now recruiting.","summary":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations is a phase 1/2 interventional study registered as NCT06378593 by 3H (Suzhou) Pharmaceuticals Co., Ltd., with 130 participants planned, started 2024-06-17 and due to reach its primary completion in 2028-06-16. Interventions recorded: 3HP-2827.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06378593","url":"https://clinicaltrials.gov/study/NCT06378593"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06378593","phase":"1/2","setting":"An Open-Label, Multi-center Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","sponsor":"3H (Suzhou) Pharmaceuticals Co., Ltd.","enrolled":130,"outcomes":[]},"route":"/trials/nct06378593/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}